来立司琼

来立司琼（INN：lerisetron；开发代号：F-0930-RS）是一种用作5-HT₃受体拮抗剂的药物。^[1]它是一种有效的止吐剂，^[2][3]目前正在临床试验中用于治疗与癌症化疗相关的恶心。^[4]

来立司琼

临床资料
其他名称	F-0930-RS
ATC码	未分配
识别信息
IUPAC命名法 1-Benzyl-2-piperazin-1-yl-1H-benzimidazole
CAS号	143257-98-1  Y
PubChem CID	65997
ChemSpider	59389 Y
UNII	Q36R82SXRG
ChEMBL	ChEMBL56900 Y
CompTox Dashboard（英语：CompTox Chemicals Dashboard） (EPA)	DTXSID90162368
化学信息
化学式	C18H20N4
摩尔质量	292.39 g·mol−1
InChI InChI=1S/C18H20N4/c1-2-6-15(7-3-1)14-22-17-9-5-4-8-16(17)20-18(22)21-12-10-19-11-13-21/h1-9,19H,10-14H2 Y Key:PWWDCRQZITYKDV-UHFFFAOYSA-N Y

参考资料

1. Orjales A, Mosquera R, Labeaga L, Rodes R. New 2-piperazinylbenzimidazole derivatives as 5-HT3 antagonists. Synthesis and pharmacological evaluation. Journal of Medicinal Chemistry. February 1997, 40 (4): 586–93. PMID 9046349. doi:10.1021/jm960442e.
2. Gomez-de-Segura IA, Grande AG, De Miguel E. Antiemetic effects of Lerisetron in radiation-induced emesis in the dog. Acta Oncologica. 1998, 37 (7–8): 759–63. PMID 10050999. doi:10.1080/028418698430160.
3. Cooper M, Sologuren A, Valiente R, Smith J. Effects of lerisetron, a new 5-HT3 receptor antagonist, on ipecacuanha-induced emesis in healthy volunteers. Arzneimittel-Forschung. 2002, 52 (9): 689–94. PMID 12404884. S2CID 24423582. doi:10.1055/s-0031-1299952.
4. Huckle R. Lerisetron. FAES. Current Opinion in Investigational Drugs. July 2003, 4 (7): 874–7. PMID 14619411.